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Abstract 
A  58-year  old  man,  affected  by  metastatic
thyroid carcinoma, experienced a progressive
bilateral visual impairment. Ophthalmic exam-
ination revealed the presence of a choroidal
mass  with  an  associated  exudative  retinal
detachment in both eyes. Twelve years before,
a  diagnosis  of  metastatic  thyroid  carcinoma
had been established and the patient had been
subject to several therapeutic procedures. 
In  May  2007,  he  received  a  radiotherapy
treatment  to  the  left  eye  with  an  episcleral
plaque and bilateral bulbar injection of beva-
cizumab. The patient had a rapid and stable
visual  acuity  recovery.  Twenty  months  after
treatment, the lesion treated with radiotherapy
was  still  stable  whereas  the  contra-lateral
lesion  had  evolved  and  determined  a  vitreal
hemorrhage.
Introduction
Choroidal  metastases  from  thyroid  cancer
are uncommon findings.
1 They often occur in
advanced stages, and generally several years
after the initial diagnosis. Main related symp-
toms can include pain and impairment of visu-
al ability. Eye metastases may cause blindness
with a rapid degradation of the patient’s quali-
ty of life.
2,3
This  paper  reports  a  case  of  bilateral
choroidal metastases in a patient in satisfacto-
ry  general  condition,  with  a  long  history  of
metastatic thyroid carcinoma initially respond-
ing to radio-metabolic therapy. 
A multimodal approach was adopted to treat
the ocular lesions, in order to restore his visu-
al acuity. After a follow-up of 18 months, the
patient’s visual ability was still good, although
multiple metastases developed in other sites. A
vitreal hemorrhage occurred 20 months after
treatment in the right eye, while the lesion
treated  with  brachytherapy  remained  unal-
tered. 
Case Report
In October 1996, a 58-year old male patient
in  satisfactory  general  condition  and  under
medical therapy for arterial hypertension, was
treated  with  total  thyroidectomy,  parathy-
roidectomy,  bilateral  cervical  lymphadenecto-
my and also with resection of a single ischio-
pubic recurrence. Histo-pathological examina-
tion  of  the  thyroid  gland  and  of  the  bone
metastasis revealed a thyroid carcinoma (G3),
confirmed by positive thyroglobulin immunos-
taining, with solid and papillary areas of oxyfil
cell-type.  No  diffusion  to  neck  lymph  nodes
was  found.  Disease  was  scored  as  T3N0M1,
IVC stage following the American Joint Cancer
Committee grouping. 
After surgery, the patient received a radio-
metabolic treatment with 131-I. During the fol-
low-up, the thyroglobulin hematic levels were
periodically checked.
From 1997 to 2007, a diffusion of multiple
metastases  was  observed;  the  largest  recur-
rences were treated by surgical resections. In
order to limit the development of recurrences,
other systemic 131-I radio-metabolic therapies
were administered (Figure 1). 
In May 2007, the patient presented a pro-
gressive visual loss in both eyes; he had a past
history of retinal venous thrombosis in his left
eye, with a residual best corrected visual acu-
ity of 20/40.
Ophthalmologic examination, performed in
May 2007, showed that ocular adnexa, extra-
ocular  movements  and  pupillary  reactions
were normal in both eyes and no exophthal-
mus was found. No pupillary defects were evi-
denced and the Best Corrected Visual Acuity
was 20/70 in the left eye (LE) and 20/25 in the
right eye (RE). 
Slit lamp examination of the anterior seg-
ment revealed only a light nuclear sclerosis.
Intra-ocular pressure was 15 mm of Hg in both
eyes. 
Ophthalmoscopic  examination  detected  a
solid  lesion  localized  in  the  posterior  pole
closely to the macula in the RE and a similar
lesion in the posterior pole of the LE, where
hypertrophic  areas  of  the  retinal  pigment
epithelium  related  to  the  previous  venous
branch occlusion were also evident (Figure 2).
B-scan  ultrasound  examination  confirmed
the  presence  of  a  slightly  elevated,  solid
choroidal mass in both eyes: in RE  it was 1.25
mm in thickness, with an associated serous
retinal detachment, in LE it measured 3.3 mm
in height and 4.8 mm in maximum base diam-
eter, with an associated serous retinal detach-
ment.
Standardized A-scan echography showed in
both  lesions  an  irregular  structure  with  a
sharp initial spike and moderate-high internal
reflectivity. 
Fundus fluorescein angiography evidenced
an area of irregular fluorescence with a mild
leakage in correspondence of the supero-tem-
poral arcade in the RE. A block of the fluores-
cence due to the retinal pigment epithelium
was noted in the posterior pole of the LE, in
correspondence  of  the  choroidal  mass.  The
ischemic maculopathy, secondary to the previ-
ous venous thrombosis, appeared as an hypo-
fluorescent lesion with late staining.
Indocyanine angiography showed the hyper-
fluorescence of the lesion in the RE, especially
in the intermediate phases, with wash out of
the dye in the late phases. In the LE, indocya-
nine angiography revealed an atrophic area of
retinal pigment epithelium and of choriocapil-
laris in correspondence of the fovea, while the
mass-lesion showed an irregular staining of
the dye in the intermediate and late phases
(Figure 2). 
Optical  Coherence  Tomography  showed  a
massive detachement of the neuro-epithelium
in  the  RE  (Figure  3);  a  hypertrophic  hyper-
reflective area of the retinal pigment epitheli-
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um (due to the previous macular scar) and a
detachment of the neuro-epithelium temporal
to  the  macula  were  also  found  in  the  LE.
Although a biopsy was not obtained from the
choroidal masses, diagnosis of presumed bilat-
eral choroidal metastases from thyroid carci-
noma was based on the patient’s medical his-
tory  and  on  ophthalmologic  findings:  the
occurrence  at  the  posterior  pole,  the  solid
appearance, the yellow-orange color, the pres-
ence of serous detachment of the sensory reti-
na, the moderate echographic internal reflec-
tivity of the masses showing an irregular inter-
nal reflectivity, the absence of demonstrable
vascular pulsations and the hyperfluorescence
with late staining  were suggestive of a sec-
ondary lesion. 
At the end of May 2007, the lesion in the LE
was treated with an episcleral 106Ru plaque
brachytherapy. 
The small lesion in the RE was not irradiat-
ed because of its small volume, its localization
close to the macula and the risk of macular
radiation  damage.  A  week  after  plaque
removal,  an  intra-vitreal  injection  of  beva-
cizumab (Avastin; Genentech, San Francisco,
CA) was performed in both eyes in order to
reduce the serous retinal detachment. 
In October 2008 an US scan indicated that
the  lesion  in  the  right  eye  remained
unchanged and the mass in the left eye was
reduced to 2.5 mm in height. OCT showed a
marked  reduction  in  height  of  the  neuro-
epithelium detachement in the right eye and a
disappearance of the temporal fluid in the left
eye  (Figure  3).  BCVA  was  still  20/20  in  the
right eye and 20/40 in the left eye. The other
metastases showed a generalized progression. 
At  the  end  of  2008,  the  patient  began  a
chemotherapy treatment with anthracycline. 
A vitreal hemorrhage occurred 20 months
after  treatment  in  the  right  eye,  while  the
lesion  treated  with  brachytherapy  remained
still unaltered. 
Discussion
Eye  metastases  are  an  important  clinical
problem,  because  they  represent  the  most
common cancer of the eye and may occur in
12% of patients with metastatic carcinomas.
4
Nevertheless, ocular metastases from thyroid
carcinoma are uncommon and bilateral syn-
chronous metastases have a rare occurrence
and represent a clinical challenge.
5-8
Taking into account all the currently avail-
able therapeutic options, a flexible approach
should be planned, depending on the clinical
situation.
The therapeutic approach should consider
the  presence  of  painful  symptomatology,
patient’s  life  expectancy,  clinical  ophthalmo-
Case Report
Figure  1.  The  figure
shows  hematic  thi-
roglobulin  concentra-
tions (in ng/mL), start-
ing  from  initial  thy-
roidectomy,  as  a  func-
tion  of  the  follow-up
time  in  months  (140
months  from  October
1996  to  June  2008);
black  dots  report  thy-
roglobulin hematic lev-
els in ng/mL (left black
scale);  red  bars  show
the  131-I  activities  in
GBq  (right  red  scale),
administered  during
the follow-up. 
Figure  2.  The  figure
shows, from top to bot-
tom, basal B-scan ultra-
sound,  fluorescein
angiography,  fundus
view,  intermediate
phase  indocyanine
angiography  and  late
phase  indocyanine
angiography  of  both
eyes before brachythera-
py. The  images  on  the
right  side  refer  to  the
left eye. 
Figure  3.  Optical
Coherence Tomography
before  brachytherapy
(top)  and  in  October
2008 (bottom) of macu-
lar  region  in  the  right
eye  (left  side)  and  the
left  eye  (right  side),
showing  the  reduction
of  fluid  (central  black
area). The red region in
the left eye corresponds
to the area interested by
a  previous  thrombotic
episode. [Rare Tumors 2009; 1:e4] [page 11]
logic assessment and general conditions.
Enucleation should be considered in pres-
ence of painful eye with secondary neovascular
glaucoma.  In  all  other  situations,  an  organ
sparing approach should be considered. 
Brachytherapy  is  particularly  effective  in
administering a high-dose to a single lesion of
small volume. This method involves temporary
placement of an episcleral radioactive device,
in correspondence to the tumor, until the pre-
scribed dose is administered. 
Generally, the treatment can be performed
in an outpatient setting and is well tolerated,
determining mild to moderate toxicity; more-
over, the results are satisfactory in terms of
visual  function  and  organ  preservation.
Photocoagulation by means of xenon or argon
ion  lasers  has  been  used  in  the  past  as  an
option in selected small choroidal melanomas.
Recently, it has been replaced by TTT that has
been proven to be effective in treating selected
small  volume  lesions.  Currently,  TTT  is  also
used as a supplement to plaque radiotherapy.
8
Bevacizumab  is  a  full-length  recombinant
humanized  monoclonal  antibody  directed
against VEGF, originally indicated for the treat-
ment  of  metastatic  colorectal  cancer.  The
antiangiogenic  properties  of  bevacizumab,
administered  via  intravenous  infusion  or
intravitreal  injection,  have  been  studied  in
patients  with  age-related  macular  degenera-
tion, choroidal neovascularization, and other
retino-choroidal vascular diseases.
9,10
Therefore, bevacizumab can reduce retinal
ischemia that could lead to radiation retinopa-
thy and exudative retinal detachment in order
to improve visual acuity and to reduce develop-
ment of neovascular glaucoma.
Macular lesions create a clinical challenge
for  which  treatment  with  intra-vitreal  beva-
cizumab seemed promising. One might theo-
rize  that,  like  laser  photocoagulation,  beva-
cizumab  may  decrease  the  ocular  ischemia
resulting from plaque radiation or may induce
a  decrease  of  vascular  permeability  in  non-
vital tissue. Clearly, testing these theories is
beyond the scope of this study. However, clini-
cal series in the literature showed encourag-
ing results in treating ischemic radiation ther-
apy. 
In the present case, intra-vitreal bevacizum-
ab administration probably achieved a reduc-
tion  of  serous  detachment  in  the  posterior
pole, thus restoring a useful visual function.
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